Willow Biosciences Inc WLLW

TOR: WLLW | ISIN: CA97111B4047   15/11/2024
0,095 CAD (+5,56%)
(+5,56%)   15/11/2024

5 september 2024 · Willow Announces Commercial License And Royalty Agreement With Kalsec Inc. · Persbericht

12 augustus 2024 · Willow Biosciences Reports Second Quarter 2024 Financial Results And Provides Corporate Update · Persbericht

7 augustus 2024 · Willow Biosciences Announces New Funded Biopesticides Research And Development Partnership After Successfully Completing Feasibility Study · Persbericht

26 juni 2024 · Willow Biosciences Provides Corporate Update And Announces Signing Of A New Partnered Program · Persbericht

30 mei 2024 · Willow Announces Multi-Product Development And Licensing Partnership With Laurus Labs For Manufacturing Active Pharmaceutical Ingredients · Persbericht

13 mei 2024 · Willow Biosciences Reports First Quarter 2024 Financial Results And Provides Corporate Update · Persbericht

29 maart 2024 · Willow Biosciences Reports Fourth Quarter And Fiscal Year 2023 Financials And Operations And Filing Of Its 2023 Aif · Persbericht

1 maart 2024 · Willow Biosciences Announces Second Strategic Investment From Kalsec · Persbericht

21 februari 2024 · Willow Biosciences Announces Strategic Investment From Kalsec To Develop Innovative Natural Food Ingredients · Persbericht

31 januari 2024 · Willow Announces Collaboration With Global Ingredient Manufacturer To Develop A More Cost-Effective, Sustainable Process For A Large Volume Active Pharmaceutical Ingredient · Persbericht

16 januari 2024 · Willow Announces Collaboration With Enterin To Develop Sustainable Intermediates And Active Pharmaceutical Ingredients · Persbericht

10 januari 2024 · Willow Plans For Significant Growth In 2024 On The Back Of A Successful 2023 · Persbericht

7 december 2023 · Willow And Leading Innovative Biopharmaceutical Company Advance Development Program To Manufacture Sustainable Intermediates And Active Pharmaceutical Ingredients · Persbericht

11 oktober 2023 · Willow Biosciences Announces Completion Of Previously Announced Convertible Debenture Financing · Persbericht

3 oktober 2023 · Willow And Suanfarma Announce Collaboration On Development Of Large Volume Anti-Infective Api Through Precision Fermentation · Persbericht

3 oktober 2023 · Willow Et Suanfarma Annoncent Leur Collaboration Pour Le Développement D'un Grand Volume D'api Anti-Infectieux Par Le Biais De La Fermentation De Précision · Persbericht

6 september 2023 · WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA · Persbericht

30 augustus 2023 · Willow Announces Filing Of Patent Application For Process To Produce Corticosteroids At Signficantly Reduced Cost · Persbericht

24 augustus 2023 · Willow Biosciences Announces Commercial Transition And Focus On Biooxi Platform · Persbericht

21 augustus 2023 · Willow Announces Collaboration With A Leading Innovative Biopharmaceutical Company To Develop Sustainable Intermediates And Active Pharmaceutical Ingredients · Persbericht

Mijn selecties